ArticleIranian journal of biotechnology2015
Th1 Immune Response Induction by Biogenic Selenium Nanoparticles in Mice with Breast Cancer: Preliminary Vaccine Model.
Article in Iranian journal of biotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 46 citations in OpenAlex.
- Selenium-Containing Compounds in Breast Cancer Therapy.Biological trace element research · 2026Review
- Therapeutic potential of greenly synthesized selenium nanoparticles against experimental cyclosporiasis.Scientific reports · 2025Article
- Clinical and mechanistic insights into biomedical application of Se-enriched probiotics and biogenic selenium nanoparticles.Biotechnology letters · 2025Review
- The role and mechanism of selenium in the prevention and progression of hepatocellular carcinoma.Frontiers in oncology · 2025Review
- Nano-based techniques: A revolutionary approach to prevent covid-19 and enhancing human awareness.Journal of drug delivery science and technology · 2023Review
- A Review of the Antibacterial, Fungicidal and Antiviral Properties of Selenium Nanoparticles.Materials (Basel, Switzerland) · 2023Review
- An insight into biofabrication of selenium nanostructures and their biomedical application.3 Biotech · 2023Review
- Biogenic Selenium Nanoparticles and Their Anticancer Effects Pertaining to Probiotic Bacteria-A Review.Antioxidants (Basel, Switzerland) · 2022Review
- Cimetidine and Ibuprofen Modulate T Cell Responses in a Mouse Model of Breast Cancer.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer.Pharmaceutics · 2022Review
- Immunomodulatory roles of selenium nanoparticles: Novel arts for potential immunotherapy strategy development.Frontiers in immunology · 2022Review
- Selenium and protozoan parasitic infections: selenocompounds and selenoproteins potential.Parasitology research · 2022Review
- The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance.Cancers · 2021Review
- Radiation Synthesis of Selenium Nanoparticles Capped withNanomaterials (Basel, Switzerland) · 2021Article
- Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies.Journal of controlled release : official journal of the Controlled Release Society · 2021Review
- Antioxidants for the Treatment of Breast Cancer: Are We There Yet?Antioxidants (Basel, Switzerland) · 2021Review
- EGFR-IL-6 Signaling Axis Mediated the Inhibitory Effect of Methylseleninic Acid on Esophageal Squamous Cell Carcinoma.Frontiers in pharmacology · 2021Article
- Prophylactic effects of biogenic selenium nanoparticles on acute toxoplasmosis: An in vivo study.Annals of medicine and surgery (2012) · 2020Article
- Selenium Nanoparticles Induce Potent Protective Immune Responses againstJournal of immunology research · 2020Article
- Selenium and selenoproteins in prostanoid metabolism and immunity.Critical reviews in biochemistry and molecular biology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor associated antigens can be viably used to enhance host immune response.
objectivesThe immunomodulatory effect of biogenic selenium nanoparticles (SeNPs) was compared between treated and untreated mice with crude antigens of 4T1 cells. MATERIALS AND
methodsFemale inbred BALB/c mice (60) were injected by cancinogenic 4T1 cells causing breast cancer. After 10 days, all tumor bearing mice were divided into 4 groups. Group 1 was daily provided oral PBS and injected by the same buffer after tumor induction and was considered as control. Group 2 received only 100 μg/day SeNPs as an oral supplement for 30 days. Group 3 was only injected with 4T1 cells crude antigens with nil supplementation of SeNPs. Group 4 animals were supplemented 100 μg/day SeNPs for 30 days and simultaneously injected with crude antigens of 4T1 cells. All antigens or PBS injections were introduced at 7, 14 and 28 days following tumor induction. Oral PBS and SeNPs supplementation initiated from the first day of tumor induction and continued up to 30 days. During tumor growth, animal weights and survival rates were monitored and at the end of the study the concentrations of different cytokines and DTH responses were measured.
resultsData clearly showed that the levels of cellular immunomodulatory components (granzyme B, IL-12, IFN-γ, and IL-2) significantly increased (
conclusionsAlthough SeNPs showed a noticeable boosting effect for the immune response in mice bearing tumor exposed to crude antigens of 4T1 cells, further complementary studies seem to be inevitable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.